Editas Medicine (EDIT) EBT Margin (2015 - 2025)
Editas Medicine (EDIT) reported EBT Margin of 332.97% for Q3 2025, up 10152932.0% year-over-year from N/an in Q3 2024, and up 76.86% quarter-over-quarter from 1438.71% in Q2 2025.
Editas Medicine (EDIT) EBT Margin (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of EBT Margin data on file, last reported at 332.97% in Q3 2025.
- EBT Margin for Q3 2025 came in at 332.97%, up 10152932.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 426.12% (down 8518.0% YoY), and the FY2024 annual result was 733.71%, down 53963.0% from the prior year.
- EBT Margin improved to 332.97% in Q3 2025 per EDIT's latest filing, from 1438.71% in the prior quarter.
- Over five years, EBT Margin peaked at 31.41% in Q4 2023 and troughed at 132683.33% in Q3 2022.
- A 5-year average of 14653.19% and a median of 873.2% in 2021 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 13205237 bps in 2022, then soared 13183965 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 332.3% in 2021, then plunged by 180 bps to 929.22% in 2022, then surged by 97 bps to 31.41% in 2023, then sank by 372 bps to 148.32% in 2024, then plunged by 124 bps to 332.97% in 2025.
- Business Quant data shows EDIT's EBT Margin at 332.97% in Q3 2025, 1438.71% in Q2 2025, and 1624.37% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -332.97% |
| Jun 30, 2025 | -1,438.71% |
| Mar 31, 2025 | -1,624.37% |
| Dec 31, 2024 | -148.32% |
| Sep 30, 2024 | -101,862.30% |
| Jun 30, 2024 | -13,178.56% |
| Mar 31, 2024 | -5,458.68% |
| Dec 31, 2023 | -31.41% |
| Sep 30, 2023 | -843.68% |
| Jun 30, 2023 | -1,395.32% |
| Mar 31, 2023 | -481.70% |
| Dec 31, 2022 | -929.22% |
| Sep 30, 2022 | -132,683.33% |
| Jun 30, 2022 | -843.89% |
| Mar 31, 2022 | -742.59% |
| Dec 31, 2021 | -332.30% |
| Sep 30, 2021 | -630.97% |
| Jun 30, 2021 | -14,579.16% |
| Mar 31, 2021 | -873.20% |
| Dec 31, 2020 | -574.87% |